Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
The United Kingdom just made history in obesity treatment. Specifically, the Medicines and Healthcare products Regulatory Agency, known as the MHRA, approved an oral version of semaglutide sold under the Wegovy brand. As a result, the UK becomes the first country in Europe to approve a daily GLP-1 receptor agonist tablet for weight management in adults.
Until now, GLP-1 treatments like Wegovy and Ozempic only came as weekly injections. This approval, however, changes that picture entirely. Consequently, patients who dislike needles or struggle with injectable therapies now have a once-daily pill as a real option.
The MHRA approved the 25mg oral semaglutide tablet as a prescription-only medicine. In particular, it targets adults living with obesity, or those who carry excess weight alongside a related health condition like high blood pressure or high cholesterol. Moreover, the pill works best alongside a reduced-calorie diet and regular exercise. It is, therefore, not a standalone fix.
The UK now joins two other regulators that have approved this formulation. Previously, the U.S. Food and Drug Administration and the United Arab Emirates Drug Establishment acted first. Thus, the MHRA becomes the third authority globally to give it the green light.
The agency based its decision on data from the OASIS 4 phase 3 clinical trial. That study followed 307 adults with obesity or excess weight who did not have type 2 diabetes. After 64 weeks, patients taking the 25mg tablet lost roughly 13.6% of their body weight on average. In contrast, the placebo group lost just 2.4%. Furthermore, among patients who followed the full treatment protocol, weight loss climbed to about 16.6%, compared to 2.7% for placebo.
Those numbers are notable for a tablet. Indeed, injectable semaglutide set a high bar in earlier trials, and the pill holds up well when patients take it correctly.
Side effects looked familiar. Specifically, nausea, vomiting, and diarrhea were the most common complaints, matching what doctors see with injectable GLP-1 therapies. Around 74% of patients in the treatment group reported these gastrointestinal side effects, whereas only 42.2% in the placebo group did. Most cases stayed mild to moderate and faded over time. Nevertheless, about 6.9% of patients stopped treatment because of side effects. That rate, however, lines up with other semaglutide studies.
GLP-1 receptor agonists copy natural incretin hormones in the body. In doing so, they cut appetite, slow digestion, and reduce calorie intake by acting on both the brain and the gut. Delivering semaglutide as a pill, though, adds a technical challenge. For this reason, the tablet needs a special absorption enhancer to work, since semaglutide does not cross the gut lining easily on its own. Still, the pill activates the same receptors and delivers similar results, just through a different route.
The timing of this approval matters. Currently, around 15 million people in the UK live with obesity. Yet pharmaceutical treatment options have not kept pace with that need. Additionally, obesity drives serious conditions like heart disease, type 2 diabetes, and joint problems. Each of those, in turn, places heavy demand on the health system.
For patients who avoided injectable GLP-1 drugs due to needle fear or injection site problems, this pill offers a genuine path forward. In fact, studies confirm that these barriers reduce treatment adherence. Therefore, a daily tablet could help more eligible patients start treatment and stick with it long term.
Access, however, still depends on a clinical assessment. Patients must meet the approved criteria, and the prescription-only status keeps the medication within medical supervision. Additionally, the pill works best as part of a broader weight management program, rather than as a quick fix.
With three major regulators now on board, attention turns naturally to reimbursement talks and health technology reviews. Ultimately, those decisions will shape how many patients can actually reach this treatment in practice.
